# A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

> **NCT07141511** · PHASE1 · COMPLETED · sponsor: **BeOne Medicines** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** BG-71332
- **DRUG:** Zanubrutinib
- **DRUG:** Sonrotoclax

## Key facts

- **NCT ID:** NCT07141511
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-24
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-02-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07141511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07141511, "A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07141511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*